{
  "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
  "docSlug": "a4fc5169399f8913c54f14d18031629c",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 42,
  "pageCount": 64,
  "prevPage": 41,
  "nextPage": 43,
  "slideType": "other",
  "function": "illustrate_case",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Includes a process flow diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/42",
  "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
  "deckJsonHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917.json",
  "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-42",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.12,
        "y": 0.0058
      },
      "kind": "callout",
      "text": "Scientific Basis: IMX-110 turns “cold” tumors “hot” in genetic (KPC) mouse models of pancreatic cancer",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "706bd28b-8ff4-4bcb-a853-85567e079312",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.95,
        "x": 0.02,
        "y": 0.0073
      },
      "kind": "diagram",
      "text": "Mechanism of action flow: Eliminating T-regs -> enabling T-cells -> eliminating vascularization",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38ad9a79-3881-4e3c-a765-2ff82e44dea5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.56,
        "x": 0.22,
        "y": 0.0018
      },
      "kind": "image",
      "text": "ImmixBio and BeiGene logos",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d41aa7a1-94bd-43e4-ad01-1c743723fbb6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.02,
        "y": 0.0033
      },
      "kind": "list",
      "text": "Study Goal: Demonstrate potential for TSTx in combination therapies; Rapid IMX-110 expansion.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "273a61a4-4f7c-48af-ab4c-8b62b96e59e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.68,
        "y": 0.0033
      },
      "kind": "list",
      "text": "Joint Alliance Committee: Members from ImmixBio & BeiGene will coordinate.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f738c3e-38f5-49d6-941c-3289fbb92fd1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.38,
        "y": 0.0033
      },
      "kind": "list",
      "text": "Combination Trial Design: IMX-110 + tislelizumab; 30 patient Phase 1b study.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da47bad1-2d31-41b9-9fd0-41fa33071c0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.02,
        "y": 0.0088
      },
      "kind": "paragraph",
      "text": "As of June 2021, in China, tislelizumab has already been approved or granted conditional approved in 5 cancer indications.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97dd299b-1500-41b8-87c6-5a7697f9485d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.8,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Clinical Trial and Supply Agreement with BeiGene for Tislelizumab (Anti-PD-1 mAb)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7132aff7-e9dc-4802-99ed-a7b3e509c3c4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "d63f52b7-86d4-4105-a0f0-f5fe020f3219",
      "evidence": "The slide uses a step-by-step visual flow to explain the mechanism of action.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}